Phase 1 N=16 PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers
Renal Impairment · Renal Insufficiency · Kidney Disease
Primary: AUC — 102.0; 168.9; 107.4; 188.5 h*ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy
Melanoma
Primary: Overall Response Rate to Treatment of Melanoma With Disulfiram and Chelated Zinc — 0 participants
Phase 2 N=63 Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
Seasonal Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
Phase 3 N=203 Treatment for Completers of the Study B7A-MC-MBCM
Diabetic Retinopathy
Primary: Sustained Moderate Visual Loss (SMVL) — 10 participants
Phase 1 N=24 A Study of LY2624803 in Japanese Participants With Transient Insomnia
Sleep Initiation and Maintenance Disorders
Primary: Wake After Sleep Onset (WASO) With LY2624803 Compared to Placebo — 58.88; 40.70; 32.27; 18.42 minutes (min) — p=0.908
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
Phase 2 N=30 Randomized Trial for Mixed Acute Rejection
Graft Rejection
Primary: Number of Patients in Each Group With Any of the Following: Rejection Reversal or Recurrent Rejection — 0; 0; 0; 2 participants
N/A N=68 A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
Intestinal FDG Uptake
Primary: SUVmax of FDG in Each Colonic Segment — 4.6; 4.3 SUV
Phase 4 N=13 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Change in Total 48 Hour Fecal Bile Acids (BA) From Baseline in Response to Treatment With Colesevelam — 1662; 3496 uM — p=0.012
Phase 3 N=151 An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain
Back Pain Lower Back Chronic
Primary: Number of Participants With Drug Related Adverse Events (AEs) or Any Serious AE's — 42; 16; 18; 4 participants
Phase 1 N=26 Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function
Multiple Myeloma
Primary: Geometric Mean Maximum Observed Serum Concentration (Cmax) of Elotuzumab Following Cycle 1, Day 1 Dose Administration - Grouping by Cockcroft-Gault Creatinine Clearance…
Phase 3 N=722 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Relapsed Multiple Myeloma · Refractory Multiple Myeloma
Primary: Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC) — 20.6; 14.7 months — p=0.012
Phase 2 N=63 Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010
Seasonal Influenza
Primary: Percentage of Participants Who Achieved Seroconversion or Significant Increase in Single Radial Hemolysis (SRH) Area Against Each of Three Vaccine Strains After One…
Phase 2 N=40 A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration
Early Lumbar Disc Degeneration
Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 2 participants
Phase 2 N=32 Intradiscal rhGDF-5 Phase I/II Clinical Trial
Degenerative Disc Disease
Primary: Neurological Assessment for Motor Function and Reflexes/Sensory — 0; 0 participants